BMS discontinues pair of IDO1, Opdivo combo trials

Bristol-Myers Squibb Co. (NYSE:BMY) discontinued two Phase III trials evaluating indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor BMS-986205 in combination with its PD-1 inhibitor Opdivo nivolumab, according to ClinicalTrials.gov. According to the

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE